Psoriatic arthritis with hyperuricemia: A case report
Keywords:
psoriatic arthritis, hyperuricemia, CASPARAbstract
Introduction: Psoriatic arthritis (PsA) has a clinical picture that resembles other arthritic diseases and is accompanied by other co-morbidities such as hyperuricemia. The diagnosis of PsA needs to be established as early as possible to reduce the morbidity of the sufferer. Case: A 52 year old woman came with complaints of pain in her fingers and wrist since two years ago. The patient has a history of psoriasis vulgaris for three years but is not taking medication regularly. The patient had his complaints checked, stated that he had gout, complaints improved but came and went. On examination of the dermatological status of the posterior truncus and manus region bilaterally and the lower extremity region, multiple erythematous papules and plaques were seen with thin scales on it. On the 2nd and 3rd digits of the right manus and 3rd digit of the left manus there is edema. Dermoscopic examination, bilateral manus x-ray and bilateral genu support the picture of PsA. The blood laboratory examination revealed hyperuricemia. Based on The Classification Criteria for PsA (CASPAR) a total of 5 points was obtained. Patients were given methotrexate tablets 7.5 mg per week orally, folic acid, sodium diclofenac, zinc and narrow band ultraviolet B phototherapy (NBUVB) 330mj/cm2 per week which was increased by 10% from the minimal erythema dose (MED) per session with a satisfactory response. Discussion: The diagnosis of PsA can be established by CASPAR criteria, namely assessing a history of psoriasis, onychodystrophy, negative results on rheumatoid factor, dactylitis and new bone formation near joints. In this case, 5 CASPAR points were obtained so that the differential diagnosis of rheumatoid arthritis and gout arthritis could be ruled out.References
Orbai AM, Flynn JA. Psoriatic Arthritis and Reactive Arthritis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick’s dermatology. 9th ed. New York: McGraw-Hill Education; 2019. p. 1126–45.
Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, et al. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. The Journal of Rheumatology. 2015;42(8):1–4.
Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian psoriatic arthritis patients. International Journal of Rheumatic Diseases. 2018;41(2):1–7.
Ogdie A, Gelfand J. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr Rheumatol Rep. 2017;17(10):1–12.
Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. International Journal of Molecular Sciences. 2017;19(58):1–19.
Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nature Reviews Disease Primers. 2019;10(8):1–14.
Tam LS, Leung YY, Li EK. Psoriatic arthritis in Asia. Rheumatology. 2009;48(12):1473–7.
Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. British Association of Dermatologists. 2011;36(11):473–8.
Tsuruta N, Imafuku S, Yutaka Narisawa. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. Journal of Dermatology. 2017;46(3):1–4.
Gottlieb AB, Mease PJ, Jackson M, Eisen D, Xia A, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. Journal of Dermatological Treatment. 2006;17(5):279–87.
Rymal E, Rizzolo D. Gout: A comprehensive review. Journal of the American Academy of Physician Assistants. 2014;27(9):1–6.
Cantini F, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassara E. Psoriatic arthritis: a systematic review. International Journal of Rheumatic Diseases. 2010;13(1):300–17.
Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;20(6):1–10.
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2011;71(6):1267–72.
Queiro R, Lorenzo A, Tejón P, Coto P, Pardo E. Obesity in psoriatic arthritis. Medicine. 2019;98(28):1–6.
Krakowski P, Gerkowicz A, Pietrzak A, Krasowska D, Jurkiewicz A, Gorzelak M, et al. Psoriatic arthritis – new perspectives. Arch Med Sci. 2019;15(3):580–9.
Mease PJ, Armstrong AW. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Adis. 2014;40(14):1–33.
Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian psoriatic arthritis patients. International Journal of Rheumatic Diseases. 2018;15(6):1–7.
AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD. Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. jrheum. 2017;11(23):1–6.
Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemiais an independent risk factor for psoriatic arthritis in psoriatic patients. Japanese Dermatological Association. 2017;10(11):1–4.
McDonald I, Connolly M, Tobin AM. A Review of Psoriasis, a Known Risk Factor for Cardiovascular Disease and Its Impact on Folate and Homocysteine Metabolism. Journal of Nutrition and Metabolism. 2012;96(5):1–4.
Schmajuk G, Tonner C, Miao Y, Yazdany J, Gannon J, Boscardin WJ, et al. Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. pone. 2016;11(12):1–10.
Rai T, Singh SK. Role of Folic Acid Supplementation in Reducing Side Effects of Oral Methotrexate in Patients of Psoriasis: A Study. ijdd. 2016;2(2):83–6.
Mogaddam MR, Ardabili N safavi, Maleki N. The Effect of Oral Zinc Therapy in Psoriasis Patients with Serum Zinc De. Research square. 2021;15(3):1–13.
Farid A, Tawfik A, Elsioufy B, Safwat G. Narrow band ultraviolet B therapy deactivates Th1/Th17 pathway and activates Th2 cytokines secretion in Egyptian psoriatic arthritis patients. Journal of Radiation Research and Applied Science. 2020;13(1):356–61.
